125 related articles for article (PubMed ID: 36315986)
1. Reply to Letter to the Editor "Re: Identification of Preoperative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upfront Surgery".
Kondo N
Dig Surg; 2022; 39(5-6):274-275. PubMed ID: 36315986
[No Abstract] [Full Text] [Related]
2. Identification of Preoperative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upfront Surgery.
Kondo N; Uemura K; Sumiyoshi T; Okada K; Seo S; Otsuka H; Kawano R; Murakami Y; Takahashi S
Dig Surg; 2021; 38(5-6):352-360. PubMed ID: 34689146
[TBL] [Abstract][Full Text] [Related]
3. Letter to "Identification of Pre-Operative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upfront Surgery".
Verma H; Jha AK; Kumar M; Singh PK; Kumar A; Paswan SS; Kumar D
Dig Surg; 2022; 39(4):201-202. PubMed ID: 35797973
[No Abstract] [Full Text] [Related]
4. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
Versteijne E; van Dam JL; Suker M; Janssen QP; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Tienhoven G; van Eijck CHJ;
J Clin Oncol; 2022 Apr; 40(11):1220-1230. PubMed ID: 35084987
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
[TBL] [Abstract][Full Text] [Related]
7. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of a Risk Score.
Kim DW; Lee SS; Kim SO; Kim JH; Kim HJ; Byun JH; Yoo C; Kim KP; Song KB; Kim SC
Radiology; 2020 Sep; 296(3):541-551. PubMed ID: 32662759
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis.
Uson Junior PLS; Carvalho L; Fernandes MLC; Botrus G; de Souza Martins R; da Silva EF; Dos Santos SSMB; Taniwaki L; Taranto P; Dutra ACP; de Oliveira Filho JB; Araujo SEA; Moura F
Sci Rep; 2022 Aug; 12(1):13592. PubMed ID: 35948602
[TBL] [Abstract][Full Text] [Related]
9. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
10. Resectability Status of Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery: Is Upfront Surgery Justified?
Miura Y; Ohgi K; Sugiura T; Okamura Y; Ashida R; Yamada M; Otsuka S; Yasunaga Y; Nakagawa M; Uesaka K
Ann Surg Oncol; 2022 Aug; 29(8):4979-4988. PubMed ID: 35362841
[TBL] [Abstract][Full Text] [Related]
11. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study.
Matsumoto I; Murakami Y; Shinzeki M; Asari S; Goto T; Tani M; Motoi F; Uemura K; Sho M; Satoi S; Honda G; Yamaue H; Unno M; Akahori T; Kwon AH; Kurata M; Ajiki T; Fukumoto T; Ku Y
Pancreatology; 2015; 15(6):674-80. PubMed ID: 26467797
[TBL] [Abstract][Full Text] [Related]
12. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
13. Radiographic Splenic Artery Involvement Is a Poor Prognostic Factor in Upfront Surgery for Patients with Resectable Pancreatic Body and Tail Cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Yamaue H
Ann Surg Oncol; 2021 Mar; 28(3):1521-1532. PubMed ID: 32705517
[TBL] [Abstract][Full Text] [Related]
14. Extrapancreatic Nerve Plexus Invasion on Imaging Predicts Poor Survival After Upfront Surgery for Anatomically Resectable Pancreatic Cancer.
Sugimoto M; Kobayashi T; Kobayashi S; Takahashi S; Konishi M; Mitsunaga S; Ikeda M; Gotohda N
Pancreas; 2020; 49(5):675-682. PubMed ID: 32433406
[TBL] [Abstract][Full Text] [Related]
15. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.
Partelli S; Bertani E; Bartolomei M; Perali C; Muffatti F; Grana CM; Schiavo Lena M; Doglioni C; Crippa S; Fazio N; Zamboni G; Falconi M
Surgery; 2018 Apr; 163(4):761-767. PubMed ID: 29284590
[TBL] [Abstract][Full Text] [Related]
16. Role of neoadjuvant treatment in resectable pancreatic cancer according to vessel invasion and increase of CA19-9 levels.
Kim HS; Lee M; Han Y; Kang JS; Kang YH; Sohn HJ; Kwon W; Lee DH; Jang JY
J Hepatobiliary Pancreat Sci; 2023 Jul; 30(7):924-934. PubMed ID: 36652346
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis.
da Costa WL; Tran Cao HS; Sheetz KH; Gu X; Norton EC; Massarweh NN
Ann Surg Oncol; 2021 Jun; 28(6):3186-3195. PubMed ID: 33174146
[TBL] [Abstract][Full Text] [Related]
18. Reply to the letter to the editor 'Borderline resectable pancreatic cancer: an evolving concept' by Petrucciani et al.
Gilbert JW; Wolpin B; Clancy T; Wang J; Mamon H; Shinagare AB; Jagannathan J; Rosenthal M
Ann Oncol; 2017 Sep; 28(9):2316. PubMed ID: 28541392
[No Abstract] [Full Text] [Related]
19. Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.
Pecorelli N; Licinio AW; Guarneri G; Aleotti F; Crippa S; Reni M; Falconi M; Balzano G
Front Oncol; 2021; 11():812102. PubMed ID: 35083158
[TBL] [Abstract][Full Text] [Related]
20. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
